# The Effect of Continuous Glucose Monitoring in Individuals With Newly Diagnosed Type 2 Diabetes

Study · id `cardio:ct-nct06471699` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06471699](<https://clinicaltrials.gov/study/NCT06471699>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06471699

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06471699. Randomized; no masking; primary purpose supportive care. Start 2024-11-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06471699, source copy `cardio:ctgov-nct06471699-2024-06-24`, retrieved 2026-10-26)
- Planned start: 2024-11-01 (anticipated) (ClinicalTrials.gov record NCT06471699, source copy `cardio:ctgov-nct06471699-2024-06-24`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06471699, source copy `cardio:ctgov-nct06471699-2024-06-24`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT06471699, source copy `cardio:ctgov-nct06471699-2024-06-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06471699-2024-06-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Continuous Glucose Monitoring in Individuals With Newly Diagnosed Type 2 Diabetes
- Acronym: CHANGE-diab
- Condition: Diabetes Type 2
- Intervention (Device): Continous Glucose Monitoring
- Intervention (Other): Self monitoring blood glucose
- Lead sponsor: Vastra Gotaland Region
- Lead sponsor class: OTHER\_GOV
- Collaborator: The Swedish Research Council
- Collaborator class: OTHER\_GOV
- Collaborator: Abbott Medical Devices
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Vastra Gotaland Region (`cardio:org-vastra-gotaland-region`)
- Registry lists this organization as a collaborator: The Swedish Research Council (`cardio:org-the-swedish-research-council`)
- Registry lists this organization as a collaborator: Abbott (`cardio:abbott`)

## Provenance

Content hash: d2070245df261d9167a9ddac83a1422c39373dc3f81e278d54a15ef07e0f7a8d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
